May 20, 2021 / 03:00PM GMT
Operator
Greetings, and welcome to the Outlook Therapeutics Virtual Clinical Day.
(Operator Instructions)
It is now my pleasure to introduce your host, Jenene Thomas, Investor Relations. Thank you, Jenene, you may begin.
Jenene D. Thomas - Jenene Thomas Communications, LLC - CEO
Thank you, Jessie. Good morning, and thank you for joining us for Outlook Therapeutics Virtual clinical day. Outlook Therapeutics is a late-stage clinical stage biopharmaceutical company working to develop ONS-5010 as the first FDA-approved ophthalmic formulation of bevacizumab for the use in retinal indications, including wet AMD, DME and BRVO. Outlook Therapeutics is publicly listed on NASDAQ and trades under the ticker symbol OTLK.
At this time, I'd like to remind our listeners that remarks made during this event may state management's intentions, beliefs, expectations or future projections. These are forward-looking statements and involve risks and uncertainties. Forward-looking statements during this event are made pursuant to the safe harbor provisions of the
Outlook Therapeutics Inc R&D Day (Virtual) Transcript
Mar 01, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers